To examine the safety and tolerance of three doses of oral vesnarinone in HIV-infected patients with CD4 count > 300 cells/mm3.

Twelve patients per dose level receive vesnarinone at 1 of 3 doses for 12 weeks. At least six patients at a given dose level must have completed 2 weeks of treatment before dose is escalated in subsequent patients.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria

Concurrent Medication: Allowed:

• Chemoprophylaxis for Pneumocystis carinii, candida, mycobacteria, and herpes simplex. Patients must have:
• Asymptomatic HIV infection.
• CD4 count > 300 cells/mm3.
• No prior AIDS-defining illness or current constitutional symptoms of HIV disease.

Exclusion Criteria

Co-existing Condition: Patients with the following symptoms or conditions are excluded:

• Current history of cardiac disease, including patients who exhibit long QT syndrome on EKG screening.
• Active malignancy other than cutaneous basal cell carcinoma or in situ carcinoma of the cervix. Concurrent Medication: Excluded:
• Antiretroviral agents, including ddI, ddC, and AZT.
• Immunosuppressive agents.
• Investigational HIV drugs/therapies including vaccines.
• Interferon.
• Steroids (other than topical).
• Hematopoietins.
• Megestrol acetate.
• Trimethoprim/sulfamethoxazole in excess of 160 mg trimethoprim and 800 mg sulfamethoxazole thrice weekly.
• Cytotoxic chemotherapy. Concurrent Treatment: Excluded:
• Radiation therapy. Patients with the following prior conditions are excluded:
• Prior history of cardiac disease.
• History of agranulocytosis or severe (grade 3) drug-induced neutropenia or documented abnormalities in granulocyte number or function. Prior Medication: Excluded:
• AZT, ddI, and ddC within 14 days prior to study entry.
• Prior cytotoxic chemotherapy.

Prior Treatment: Excluded:

• Radiation therapy (including electron beam irradiation) within 30 days prior to study entry. Active illicit drug abuse.